Argent Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Argent Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40	Closed	–	–	459
2019 Q4	$0	Buy	+40	New	+$765	﹤0.01%	548

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Argent Advisors's TAK Position: Q1 2020 in Review

Argent Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2020, closing a stake of 40 shares.

Argent Advisors first reported a position in TAK in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

Argent Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2020 after selling out during the quarter.
Argent Advisors sold 40 Takeda Pharmaceutical shares in Q1 2020.
Argent Advisors first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 1 quarter.
Argent Advisors's Takeda Pharmaceutical position peaked at $0 in Q4 2019.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.